Gossamer Bio

Gossamer Bio Net Income

The Net Income of Gossamer Bio (GOSS) as of Nov 20, 2026 is -170.37 M USD. In the previous year, Net Income was -56.53 M USD — a change of 201.39% (lower).

Net Income

-170.37 MUSD

YoY

201.39%

Last updated:

In 2025, Gossamer Bio's profit amounted to -170.37 M USD, a 201.39% increase from the -56.53 M USD profit recorded in the previous year.

The Gossamer Bio Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Income
Date
Net Income
Jan 1, 2023
-179.82 M USD
Jan 1, 2024
-56.53 M USD
Jan 1, 2025
-170.37 M USD
Jan 1, 2026 (e)
-53.56 M USD
Jan 1, 2027 (e)
-17.99 M USD
Jan 1, 2028 (e)
-11.11 M USD
Jan 1, 2029 (e)
2.83 M USD
Jan 1, 2030 (e)
20.13 M USD
The Gossamer Bio Net Income history
YEARNet IncomeYoY
est20.13 MUSD+610.28%
est2.83 MUSD-125.51%
est-11.11 MUSD-38.26%
est-17.99 MUSD-66.42%
est-53.56 MUSD-68.56%
-170.37 MUSD+201.39%
-56.53 MUSD-68.56%
-179.82 MUSD-21.61%
-229.38 MUSD-1.98%
-234.00 MUSD-3.84%
-243.36 MUSD+34.59%
-180.82 MUSD+23.03%
-146.97 MUSD+2,070.57%
-6.77 MUSD+8,057.83%
-83,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Gossamer Bio Revenue

Gossamer Bio Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-183.76 M USD
-179.82 M USD
Jan 1, 2024
114.70 M USD
-59.92 M USD
-56.53 M USD
Jan 1, 2025
48.47 M USD
-161.44 M USD
-170.37 M USD
Jan 1, 2026 (e)
64.61 M USD
-52.30 M USD
-53.56 M USD
Jan 1, 2027 (e)
17.94 M USD
-11.99 M USD
-17.99 M USD
Jan 1, 2028 (e)
82.78 M USD
-554,433.00 USD
-11.11 M USD
Jan 1, 2029 (e)
165.99 M USD
15.59 M USD
2.83 M USD
Jan 1, 2030 (e)
272.91 M USD
37.48 M USD
20.13 M USD

Gossamer Bio Margins

Gossamer Bio stock margins

The Gossamer Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Gossamer Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Gossamer Bio.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
97.93 %
- %
- %
Jan 1, 2024
100.00 %
-52.24 %
-49.28 %
Jan 1, 2025
97.93 %
-333.06 %
-351.49 %
Jan 1, 2026 (e)
97.93 %
-80.94 %
-82.91 %
Jan 1, 2027 (e)
97.93 %
-66.81 %
-100.25 %
Jan 1, 2028 (e)
97.93 %
-0.67 %
-13.42 %
Jan 1, 2029 (e)
97.93 %
9.39 %
1.71 %
Jan 1, 2030 (e)
97.93 %
13.73 %
7.37 %

Gossamer Bio Stock analysis

What does Gossamer Bio do? The company Gossamer Bio Inc. was founded in 2015 by Faheem Hasnain and Sheila Gujrathi. The founders had previously worked at various biotechnology companies and now wanted to start their own company to develop innovative products in the field of immunology. Gossamer Bio is headquartered in San Diego, California and currently employs around 200 people. The company specializes in researching and developing therapeutics for a wide range of diseases, including respiratory diseases, cancer, immunological disorders, and infections. Gossamer Bio's business model is based on identifying promising new drug candidates and subsequently developing therapeutics that have the potential to improve patients' lives. Key pillars of the business model include partnerships with established companies and investors, as well as the rapid and efficient conduct of clinical trials. Gossamer Bio's portfolio includes various pipeline programs in different stages of development. An important focus is on the development of new drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). A promising drug candidate in this area is GB001, an inhalation medication that aims to reduce inflammation in the airways. Another important program of Gossamer Bio is the development of therapeutics for the treatment of cancer. The company focuses on the development of drugs that target the body's immune system to specifically fight tumor cells. A promising drug candidate in this area is GB1275, an antibody that specifically targets a protein overexpressed by some types of cancer. In addition to these two focus areas, Gossamer Bio also has programs in the development of therapeutics for the treatment of immunological disorders such as inflammatory bowel disease and rheumatoid arthritis, as well as for the treatment of infections such as COVID-19. Overall, Gossamer Bio has a wide range of promising drug candidates that have the potential to revolutionize the field of immunology and disease management. The company is well positioned to make significant progress in the development of new therapeutics in the coming years and improve the lives of millions of patients worldwide. Gossamer Bio is one of the most popular companies on Eulerpool.

Net Income Details

Understanding Gossamer Bio's Profit Margins

The profit margins of Gossamer Bio represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Gossamer Bio's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Gossamer Bio's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Gossamer Bio's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Gossamer Bio’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Gossamer Bio stock

Net Income of Gossamer Bio is -170.37 M USD in 2025.

Net Income of Gossamer Bio changed from -56.53 M USD to -170.37 M USD, representing a 201.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Income Gossamer Bio since 2006 – with annual values, charts, and detailed analysis.

The achievement of a profit is the biggest goal of a company. The profit can be used for distribution or reinvestment. The profit (also called annual surplus or EAT, earnings after taxes) is the positive difference between income and expenses in a period as shown in the income statement. A negative annual surplus is called annual loss. Both performance measures are also combined under the neutral term annual result.

The Net Income is derived from all revenues / sales minus the expenses in the period under review. The following overview clearly shows which positions contribute to the annual surplus and where the differences lie compared to other variants of profit such as EBT, EBIT, and EBITDA.

Net Income's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Income's Gossamer Bio historically and in real time.

The profit in evaluating a stock

History, usage, calculation, and application of earnings in securities trading.

The history of earnings dates back to the beginnings of modern business organization. Since the beginning of industrialization, companies have been established to generate profits, and profits have been considered an essential part of corporate management. In recent years, the importance of earnings for investors has continued to rise, as many investors seek to find stocks that generate solid earnings.

Use of Profits

In securities trading, profits are used to determine the value of a stock. A company that generates profits is considered financially healthy and its stocks are valued higher, while a company that does not generate profits is considered less reliable and therefore receives a lower valuation. Investors can review the profits of each company by examining the relevant documents such as the income statement, the annual financial statements, and the income tax audits.

Calculation of profits

There are several different ways to calculate profits. The simplest way to calculate profits is by calculating net earnings. Net earnings are calculated by subtracting the company's expenses from its revenue. Another way to calculate profits is by calculating operating income. Operating income is calculated by subtracting the company's materials costs and employee wages and salaries from its revenue.

Use of profits

There are many different ways in which investors can use profits when evaluating stocks. One example is calculating the price-to-earnings ratio (P/E ratio). The P/E ratio is the relationship between the price of a stock and the company's earnings. When calculating the P/E ratio, the stock price is divided by the company's earnings. A low P/E value indicates that the stock has a good price-performance ratio, and a high P/E value indicates that the stock has a poor price-performance ratio.

Advantages and disadvantages of using profits

There are many advantages to using earnings in securities trading. Firstly, investors can check the financial health of a company by analyzing earnings. Secondly, investors can make a better decision about the valuation of a stock by calculating the P/E ratio. Thirdly, investors can reduce their risk by choosing stocks with a low P/E ratio.

However, there are also some drawbacks to relying on profits. Firstly, profits can be distorted if a company increases its profits through cost-cutting measures. Secondly, profits can present an inaccurate picture of a company's financial health if they are not calculated correctly. Thirdly, profits may not always be a reliable indicator of a company's future, as they can easily fluctuate.

t('components_kpi_Explanation_34')

Overall, it can be said that profits in securities trading are an important indicator of a company's financial health. Investors can analyze profits to get a better understanding of the company's financial health and make informed decisions about stock valuation. However, there are some disadvantages to using profits as they can sometimes be distorted or inaccurate. Therefore, it is important for investors to be cautious and carefully analyze profits before making a decision to buy or sell stocks.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Gossamer Bio

All Key Metrics — Gossamer Bio